ADC Therapeutics SA

ADCT

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

OrbiMed Advisors Redmile Group Eventide Asset Management

Position Trend

Feb 13, 2026

$11.9M

1 fund

Feb 17, 2026

$75.9M

2 funds

+539% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 5,822,854Value: $20.6M

# Signal Note: OrbiMed Initiates $20.6M Position in ADC Therapeutics OrbiMed's entry into ADCT likely reflects conviction in the company's lead candidate loncastuximab tesirine (Zynlonta), a CD19-directed antibody-drug conjugate approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with near-term catalysts including label expansions and combination trial readouts. The $20.6M position (5.8M shares at ~$3.54/share) suggests OrbiMed sees asymmetric upside, possibly ahead of pivotal data in follicular lymphoma or partnership announcements that could de-risk the company's burn rate. This signals institutional validation for ADCT's commercial execution and pipeline potential in the growing ADC space.

Redmile GroupNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ORIC3 funds RNA2 funds IRON2 funds ARGX2 funds PRAX2 funds ALNY2 funds AXSM2 funds EWTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

**SIGNAL NOTE: Redmile initiates $55.3M position in ADCT** Redmile's entry into ADC Therapeutics suggests conviction in the company's lead program loncastuximab tesirine (Zynlonta), an anti-CD19 antibody-drug conjugate approved for relapsed/refractory diffuse large B-cell lymphoma. The $55.3M stake (meaningful but not controlling) indicates confidence in either label expansion potential (DLBCL frontline or other B-cell malignancies) or pipeline progression, though near-term catalysts depend on ongoing clinical readouts. Green's healthcare crossover mandate typically reflects thesis around clinical/commercial inflection points rather than speculative positioning.